Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?

N. Rosencher,L. Bellamy,L. Arnaout

DOI: https://doi.org/10.1016/j.acvd.2009.02.007

IF: 3.196

2009-04-01

Archives of Cardiovascular Diseases

Abstract:

What problem does this paper attempt to address?

Altitude-Related Disorders on Mount Kilimanjaro, Tanzania: Two-Year Survey in a Local Referral Center

Marieke C J Dekker,Alex Mremi,Kajiru G Kilonzo,Gissela Nyakunga,Francis Sakita,Mark Mvungi,Sarah J Urasa,Gileard Masenga,William P Howlett

DOI: https://doi.org/10.1016/j.wem.2020.10.003

Abstract:Introduction: A significant number of climbers on Mount Kilimanjaro are affected by altitude-related disorders. The aim of this study was to determine the main causes of morbidity and mortality in a representative cohort of climbers based on local hospital records. Methods: We conducted a 2-y retrospective chart review of all patients presenting to the main referral hospital in the region after a climb on Mount Kilimanjaro, including all relevant records and referrals for postmortem studies. Results: We identified 62 climbers who presented to the hospital: 47 inpatients and 15 outpatients. Fifty-six presented with high altitude illness, which included acute mountain sickness (n=8; 14%), high altitude pulmonary edema (HAPE) (n=30; 54%), high altitude cerebral edema (HACE) (n=7; 12%), and combined HAPE/HACE (n=11; 20%). The mean altitude of symptom onset ranged from 4600±750 m for HAPE to 5000±430 m for HAPE/HACE. The vast majority of inpatients (n=41; 87%) were improved on discharge. Twenty-one deceased climbers, most having died while climbing (n=17; 81%), underwent postmortem evaluation. Causes of death were HAPE (n=16; 76%), HAPE/HACE (n=3; 14%), trauma (1), and cardiopulmonary (1). Conclusions: HAPE was the main cause of death during climbing as well as for hospital admissions. The vast majority of climbers who presented to hospital made a full recovery.
Severe high-altitude cerebral edema on the Inca Trail

Oliver Hart

DOI: https://doi.org/10.2310/7060.2004.13528

Abstract:The following case history serves to reiterate the practical dangers of trekking at altitude. Despite the latter-day rise in the profile of altitude-related dangers, risks can still be understated to clients and poorly prepared for, even on commonly walked routes. Financial pressures can sometimes outweigh safety considerations.
Clinical features of patients with severe altitude illness in Nepal

Eyal Leshem,Prativa Pandey,David R Shlim,Kazuko Hiramatsu,Yechezkel Sidi,Eli Schwartz

DOI: https://doi.org/10.1111/j.1708-8305.2008.00229.x

Abstract:Background: Trekking in Nepal is a popular adventure travel activity involving more than 80,000 people of all ages annually. This study focuses on the demographic characteristics and clinical course of altitude illness patients evacuated to Kathmandu and estimates the rates of evacuation in different regions of Nepal. Methods: During the years 1999 to 2006, all patients who presented with altitude illness to the CIWEC clinic in Kathmandu were evaluated and included in the study if the final diagnosis was compatible with high-altitude cerebral edema (HACE), high-altitude pulmonary edema (HAPE), or acute mountain sickness (AMS). Altitude illness-related deaths were reported according to death certificates issued by selected embassies in Kathmandu. Results: A total of 406 patients were evaluated, among them 327 retrospectively and 79 prospectively. HACE was diagnosed in 21%, HAPE in 34%, combined HAPE and HACE in 27%, and AMS in 18%. Mean patient age was older than trekker controls (44 +/- 13.5 vs 38.6 +/- 13.9 y, p < 0.0001). Everest region trekkers were more likely to be evacuated for altitude illness than trekkers in other regions. The estimated incidence of altitude illness-related death was 7.7/100,000 trekkers. Most altitude illness symptoms resolved completely within 2 days of evacuation. Conclusions: Altitude illness that results in evacuation occurs more commonly among trekkers in the Everest region and among older trekkers. The outcome of all persons evacuated for altitude illness was uniformly good, and the rate of recovery was rapid. However, the incidence of altitude illness-related death continued to rise over past decade.
Acute high-altitude sickness

Andrew M Luks,Erik R Swenson,Peter Bärtsch

DOI: https://doi.org/10.1183/16000617.0096-2016

2017-01-31

Abstract:At any point 1-5 days following ascent to altitudes ≥2500 m, individuals are at risk of developing one of three forms of acute altitude illness: acute mountain sickness, a syndrome of nonspecific symptoms including headache, lassitude, dizziness and nausea; high-altitude cerebral oedema, a potentially fatal illness characterised by ataxia, decreased consciousness and characteristic changes on magnetic resonance imaging; and high-altitude pulmonary oedema, a noncardiogenic form of pulmonary oedema resulting from excessive hypoxic pulmonary vasoconstriction which can be fatal if not recognised and treated promptly. This review provides detailed information about each of these important clinical entities. After reviewing the clinical features, epidemiology and current understanding of the pathophysiology of each disorder, we describe the current pharmacological and nonpharmacological approaches to the prevention and treatment of these diseases.
Research advances in pathogenesis and prophylactic measures of acute high altitude illness

Yunhong Li,Yujing Zhang,Ying Zhang

DOI: https://doi.org/10.1016/j.rmed.2018.11.004

IF: 4.3

2018-01-01

Respiratory Medicine

Abstract:After ascent to high altitude (≥2500 m), the inability of the human body to adapt to the hypobaric and hypoxia environment can induce tissue hypoxia, then a series of high altitude illnesses including acute mountain sickness (AMS), high altitude pulmonary edema (HAPE), and high altitude cerebral edema (HACE) would develop. Symptoms of AMS include headache, dizziness, nausea, and vomiting; HAPE is characterized by orthopnea, breathlessness at rest, cough, pink frothy sputum, and results in obvious pulmonary edema that poses significant harm to people; HACE is characterized by ataxia and decreased consciousness, leading to coma and brain herniation which would be fatal if not treated promptly. This review article provides a current understanding of the pathophysiology of these three forms of high altitude illness and elaborates the current prevention and treatment measures of these diseases.
Elevated C-Reactive Protein Augments Increased Arterial Stiffness in Subjects With the Metabolic Syndrome

H. Tomiyama,Yutaka Koji,Minoru Yambe,Kohki Motobe,K. Shiina,Zaydun Gulnisa,Yoshio Yamamoto,A. Yamashina

DOI: https://doi.org/10.1161/01.HYP.0000165018.63523.8a

IF: 9.8968

2005-05-01

Hypertension

Abstract:We examined whether the presence of an increasing number of metabolic syndrome “disorders” was associated with an increasing pulse wave velocity, which is recognized as a marker of cardiovascular risk, and evaluated whether an elevated plasma C-reactive protein level augments this increasing pulse wave velocity. Using a cross-sectional study design, C-reactive protein, metabolic syndrome–related anthropometric parameters, and pulse wave velocity were measured in 5752 middle-aged Japanese men (44±10 years old). In linear regression analyses, all of the metabolic “disorders” and the logarithm of the C-reactive protein significantly correlated with pulse wave velocity. Multiple linear regression analysis demonstrated that triglycerides, HDL cholesterol, mean blood pressure, fasting glucose, and the logarithm of the C-reactive protein were significant independent positive predictors of pulse wave velocity (R-square=0.38). The presence of an increasing number of metabolic “disorders” in the subjects was associated with an increasing pulse wave velocity (no disorders 1228±139 cm/s ≥3 disorders 1437±250 cm/s; P<0.01). Among subjects with the metabolic syndrome, pulse wave velocity was higher in cases with (1508±278 cm/s) than in those without an elevated C-reactive protein (1427±243 cm/s; P<0.01). In conclusion, an increase in arterial stiffness may constitute a pathophysiological basis for the increased risk of cardiovascular disease in patients with the metabolic syndrome and that an elevated C-reactive protein level may aggravate this cardiovascular risk.
A trek to the top: a review of acute mountain sickness

M J Porcelli,G M Gugelchuk

Abstract:Acute mountain sickness (AMS) affects, to varying degrees, all travelers to high altitudes (elevations greater than 5280 feet). In a small percentage of patients, AMS can lead to high-altitude pulmonary edema (HAPE) or high-altitude cerebral edema (HACE). Symptoms of AMS range from a combination of headache, insomnia, anorexia, nausea, and dizziness, to more serious manifestations, such as vomiting, dyspnea, muscle weakness, oliguria, peripheral edema, and retinal hemorrhage. Although the primary cause of these symptoms is related to the reduced oxygen content and humidity of the ambient air at high altitudes, the physiologic pathway relating hypoxemia to AMS and its sequelae remains unclear. Tips on self-diagnosis and symptom recognition are critical elements to be included in educating patients who are contemplating a trip to high altitudes. Preventive strategies include allowing 2 days of acclimatization before engaging in strenuous exercise at high altitudes, avoiding alcohol, and increasing fluid intake. Conditioning exercise for patients older than 35 years is also recommended before departure. A high-carbohydrate, low-fat, low-salt diet can also aid in preventing the onset of AMS. Acetazolamide (125 mg two or three times daily, or once at bedtime) has also been shown to reduce susceptibility to AMS and the incidence of HAPE and HACE. Although effective in treating cerebral symptoms of AMS, dexamethasone is not routinely recommended as a prophylactic agent for AMS.
High-altitude cerebral edema with absence of headache

Oyvind Thomassen,Sven Chr Skaiaa

DOI: https://doi.org/10.1580/1080-6032(2007)18[45:hcewoh]2.0.co;2

Abstract:Headache is the cardinal symptom of acute mountain sickness (AMS). The headache normally worsens, with increased cerebral affection and the development of high-altitude cerebral edema (HACE). A Norwegian expedition aimed to climb Baruntse (7129 m) in Nepal in 2003. At 5400 m a 35-year-old man felt exhausted. The next day he aborted his attempt at further climbing as a result of extreme fatigue. Over the next 24 hours he developed cough, dyspnea, and severe hypoxia before progressing to ataxia and blurred vision. At no point did he experience headache or nausea. The patient was evacuated by helicopter. He improved immediately after descent and recovered completely within a week. The speed of progression from AMS to HACE varies. Abrupt onset of HACE is occasionally reported. High-altitude pulmonary edema (HAPE) may induce severe hypoxia that can lead to rapid development of HACE. High-altitude cerebral edema in the setting of HAPE was the most likely diagnosis despite the unusual lack of headache. Rapid onset of HAPE with subsequent severe desaturation should raise awareness of the development of HACE, even in the absence of headache.
Mitral valve obstruction in a case of bacterial endocarditis due to Corynebacterium hofmanii: echocardiographic diagnosis.

S. Rubler,L. Harvey,A. Avitabile,T. Abenavoli

1982-10-01

Abstract:
High-altitude Cerebral Edema and High-altitude Pulmonary Edema Diagnosed in the Desert: A Case Report

Bryn Walsh,Suneil Agrawal

DOI: https://doi.org/10.5811/cpcem.3851

Abstract:Introduction: Acute mountain sickness, high-altitude pulmonary edema (HAPE), and high-altitude cerebral edema (HACE) are a spectrum of high-altitude conditions, with HACE being the most life-threatening. Most cases develop at altitudes of greater than 4,000 meters (∼13,000 feet) above sea level and after one to five days. Case report: A previously healthy 46-year-old female presented to the emergency department with ataxia, altered mental status, and vomiting that developed after rapidly ascending to ∼2,400 meters (∼7,800 feet) above sea level. She was treated for HACE and HAPE with resolution of her symptoms within 24 hours. Conclusion: High-altitude pulmonary edema and HACE can develop rapidly and at moderate altitudes. Expeditious recognition and treatment is imperative to avoid life-threatening complications.
Altitude illnesses

Hannes Gatterer,Francisco C. Villafuerte,Silvia Ulrich,Sanjeeb S. Bhandari,Linda E. Keyes,Martin Burtscher

DOI: https://doi.org/10.1038/s41572-024-00526-w

IF: 81.5

2024-06-21

Nature Reviews Disease Primers

Abstract:Millions of people visit high-altitude regions annually and more than 80 million live permanently above 2,500 m. Acute high-altitude exposure can trigger high-altitude illnesses (HAIs), including acute mountain sickness (AMS), high-altitude cerebral oedema (HACE) and high-altitude pulmonary oedema (HAPE). Chronic mountain sickness (CMS) can affect high-altitude resident populations worldwide. The prevalence of acute HAIs varies according to acclimatization status, rate of ascent and individual susceptibility. AMS, characterized by headache, nausea, dizziness and fatigue, is usually benign and self-limiting, and has been linked to hypoxia-induced cerebral blood volume increases, inflammation and related trigeminovascular system activation. Disruption of the blood–brain barrier leads to HACE, characterized by altered mental status and ataxia, and increased pulmonary capillary pressure, and related stress failure induces HAPE, characterized by dyspnoea, cough and exercise intolerance. Both conditions are progressive and life-threatening, requiring immediate medical intervention. Treatment includes supplemental oxygen and descent with appropriate pharmacological therapy. Preventive measures include slow ascent, pre-acclimatization and, in some instances, medications. CMS is characterized by excessive erythrocytosis and related clinical symptoms. In severe CMS, temporary or permanent relocation to low altitude is recommended. Future research should focus on more objective diagnostic tools to enable prompt treatment, improved identification of individual susceptibilities and effective acclimatization and prevention options.

medicine, general & internal
Atypical High-Altitude Cerebral Edema Presentation at an Altitude of Less Than 3000 Meters Elevation: A Case Report

Todd Bolotin,Kayla E Prokopakis,Bruce Becker

DOI: https://doi.org/10.2147/OAEM.S336951

2022-03-29

Abstract:Introduction: Atypical presentations of high altitude cerebral edema may have a stuttering course that can be similar to more common and benign pathology at a lower altitude than typically causes high altitude cerebral edema. Case report: A healthy 27-year-old male presented to a medical clinic situated at an altitude of 2829 meters with a "migraine" headache and nausea. He reported several episodes of 'blurry vision' each lasting seconds to a minute over the previous day. Symptoms had started four to five days after ascending from his home at sea level. The visual symptoms did not recur while he was in the clinic and his headache and nausea improved after oral medication. The physician recommended advanced imaging at the local hospital, but he declined and was discharged. The following day while riding a ski lift between 2830 and 3782 meters, he had a one-hour episode of visual disturbance with an intense headache. He was directed to proceed to the hospital for magnetic resonance imaging of the brain which demonstrated changes in his corpus callosum consistent with high altitude cerebral edema and he was evacuated to 1609 meters. Conclusion: An index of suspicion for high altitude cerebral edema must be maintained for any new neurological symptoms in unacclimatized individuals presenting to high alpine environments even those lower than typically associated with this high mortality condition.
Intraocular pressure effects of multiple doses of drugs applied to glaucomatous monkey eyes.

P. Lee,S. Podos,J. Serle,C. Camras,C. Severin

DOI: https://doi.org/10.1001/ARCHOPHT.1987.01060020103038

1987-02-01

A M A Archives of Ophthalmology

Abstract:The effects of multiple dosing with 0.5% timolol maleate, 2% epinephrine hydrochloride, 4% pilocarpine hydrochloride, 1% vanadate, 1% forskolin (nonproprietary name, colforsin), or 0.5% prostaglandin F2 alpha on intraocular pressure (IOP) were each tested on eight cynomolgus monkey eyes in which glaucoma was induced by photocoagulating the trabecular meshwork with the argon laser. The week prior to drug therapy, baseline IOP measurements were carried out at hourly intervals from 9:30 am to 3:30 pm on three days. One to two days later, therapy was initiated. Each drug was applied topically to both eyes of each monkey twice daily for at least four days. The IOP was measured with a calibrated pneumatonometer at the same hourly intervals on treatment days as on the baseline days. The IOP at each time of day on treatment days was compared with the average baseline IOP measured at the corresponding time of day. Topical application of timolol, epinephrine, pilocarpine, vanadate, and prostaglandin F2 alpha significantly reduced IOP without evidence of tolerance or tachyphylaxis during the course of therapy. Forskolin did not significantly decrease IOP after the second day of treatment.
ATP Depletion-induced Actin Rearrangement Reduces Cell Adhesion via p38 MAPK-HSP27 Signaling in Renal Proximal Tubule Cells

Jun Du,Lijia Zhang,Yu Yang,Weixing Li,Ling Chen,Y. Ge,Chongqi Sun,Yichao Zhu,L. Gu

DOI: https://doi.org/10.1159/000303055

2010-03-01

Cellular Physiology and Biochemistry

Abstract:Ischemia causes desquamation of proximal tubular epithelial cells leading to acute renal failure. However, the molecular mechanisms underlying the detachment of proximal tubule cells remain unknown. In this study, we reported that ATP depletion resulted in actin polymerization, a shift of filamentous actin from web-like structure to fragmented parallel stress fibers, followed by a reduction of cellular adhesion ability. The pre-treatment with Jasplakinolide, an actin stabilizer, prevented ATP depletion-induced actin polymerization and reduction of cell adhesion, indicating that the cytoskeleton reorganization decreased the cellular adhesion ability. Furthermore, the ATP depletion markedly increased the levels of p38MAPK and HSP27 phosphorylation with enhanced translocation of phosphorylated HSP27 from cytoskeleton to cytoplasm. The inhibition of p38MAPK by SB203580 blocked the ATP depletion to induce HSP27 phosphorylation and actin polymerization. These findings suggest that ischemia remodels filamentous actin leading to desquamation of proximal tubular epithelial cells through p38 MAPK-HSP27 signaling.
Effect of penetration enhancers and iontophoresis on the ultrastructure and cholecystokinin-8 permeability through porcine skin.

K. Bhatia,S. Gao,T. Freeman,J. Singh

DOI: https://doi.org/10.1021/JS970023K

1997-09-01

Journal of Pharmacy and Science

Abstract:The present study explores the effect of chemical penetration enhancers and iontophoresis on the in vitro permeability of cholecystokinin-8 (CCK-8) through porcine epidermis and on the ultrastructural changes in stratum corneum as observed by transmission electron microscopy (TEM). Enhancer [i.e., ethanol (EtOH), and 10% oleic acid in combination with ethanol (OA/EtOH)] pretreatment significantly increased (p < 0.01) the permeability coefficient of CCK-8 in comparison with the control (pretreated epidermis without enhancer). Iontophoresis further increased the permeability of CCK-8 (p < 0.01) through the enhancer-pretreated epidermis in comparison with the control. These results showed the synergistic effect of iontophoresis and enhancers such as OA/EtOH that provides an additional driving force to maintain and control the target flux of CCK-8. The ultrastructure of stratum corneum treated with ethanol demonstrated a loss of structural components in the superficial stratum corneum cell layers. OA/EtOH transformed the highly compact cells of stratum corneum into a looser network of filaments, creating an increased free volume and greater intracellular surface area. Treatment of stratum corneum with OA/EtOH followed by iontophoresis resulted in further swelling of stratum corneum cell layers. In conclusion, OA/EtOH in combination with iontophoresis increased the permeability of CCK-8 by loosening and swelling of stratum corneum cell layers.
Case report: Severe rhabdomyolysis and acute liver injury in a high-altitude mountain climber

Yun-Chih Yeh,Chien-Chou Chen,Shih-Hua Lin

DOI: https://doi.org/10.3389/fmed.2022.917355

IF: 3.9

2022-08-08

Frontiers in Medicine

Abstract:Concurrent severe rhabdomyolysis and acute liver damage are rarely reported in the setting of acute high-altitude illness (AHAI). We described a 53-year-old healthy mountain climber who experienced headache and dyspnea at the summit of Snow Mountain (Xueshan; 3,886 m above sea level) and presented to the emergency room with generalized malaise, diffuse muscle pain, and tea-colored urine. His consciousness was alert, and he had a blood pressure of 114/74 mmHg, heart rate of 66/min, and body temperature of 36.8°C. Myalgia of the bilateral lower limbs, diminished skin turgor, dry oral mucosa, and tea-colored urine were notable. Urinalysis showed positive occult blood without red blood cells. The most striking blood laboratory data included creatine kinase (CK) 33,765 IU/L, inappropriately high aspartate aminotransferase (AST) 2,882 IU/L and alanine aminotransferase (ALT) 2,259 IU/L (CK/AST ratio 11.7, CK/ALT ratio 14.9), creatinine 1.5 mg/dl, serum urea nitrogen (BUN) 26 mg/dl, total bilirubin 1.7 mg/dl, ammonia 147 μg/ml, lactate 2.5 mmol/L, and prothrombin time 17.8 s. The meticulous search for the underlying causes of acute liver injury was non-revealing. With volume repletion, mannitol use, and urine alkalization coupled with avoidance of nephrotoxic and hepatotoxic agents, his clinical features and laboratory abnormality completely resolved in 3 weeks. Despite rarity, severe rhabdomyolysis and/oracute liver injury as a potential life-threatening condition requiring urgent management may occur in high-altitude hypobaric hypoxia.

medicine, general & internal
Secundum Atrial Septal Defect: Nonoperative Closure During Cardiac Catheterization

T. D. King,S. Thompson,C. Steiner,N. Mills

DOI: https://doi.org/10.1001/JAMA.1976.03260490024013

1976-06-07

Abstract:A 17-year-old girl had clinical and cardiac catheterization findings compatible with a secundum atrial septal defect. During cardiac catheterization, the atrial septal defect was sized and closed using a transvenous umbrella technique. (JAMA235:2506-2509, 1976)
Altitude-Related Illness

Jessica Gehner

DOI: https://doi.org/10.1016/j.emc.2024.02.013

Abstract:Altitude-related illness occurs as a result of inadequate acclimatization. The mainstay of prevention is a slow, graded ascent profile which gives the body time to respond to a low-oxygen environment. The diagnosis of these conditions is often difficult in resource-limited environments, so history and a physical exam are key in identifying patients who will require descent and evacuation. Treatment modalities such as supplemental oxygen, portable hyperbaric chambers, and medications, are all temporizing measures until the patient can be safely evacuated to a lower elevation.
The impact of laws on HIV and STD prevention.

Cari Cason,Nan Orrock,K. Schmitt,J. Tesoriero,Z. Lazzarini,E. Sumartojo

Abstract:HIV and sexually transmitted diseases (STDs) are major public health problems in the United States. Since the start of the epidemic, nearly 800,000 persons have been reported with AIDS, and approximately 900,000 Americans are currently living with HIV infection. Each year, 15 million people in the United States become infected with one or more STDs. The direct and indirect costs of the major STDs--not including HIV infection--and their complications are estimated to total at least $10 billion annually. This article underscores the importance of law and other structural factors in the prevention and treatment of HIV and STDs. It describes state-level laws on STD screening, name-based reporting of STDs, name-based reporting of HIV and HIV partner notification implementation, and the impact of laws on STD and HIV risk behaviors and prevention services. More broadly, the article focuses on how the law influences the vulnerability or resilience of persons facing the risk of STDs, HIV infection, or AIDS.
Evaluation and Management of the Individual with Recurrent High Altitude Pulmonary Edema

Andrew M Luks,Colin K Grissom

DOI: https://doi.org/10.1089/ham.2024.0024

Abstract:Luks AM, Grissom CK. Evaluation and Management of the Individual with Recurrent HAPE. High Alt Med Biol. 25:238-246, 2024. Individuals with a history of acute altitude illness often seek recommendations from medical providers on how to prevent such problems on future ascents to high elevation. Although many of these cases can be managed with pharmacologic prophylaxis and counseling about the appropriate rate of ascent alone, there are some situations in which further diagnostic evaluation may also be warranted. One such situation is the individual with recurrent episodes of high altitude pulmonary edema (HAPE), as one of several predisposing factors may be present that warrants additional interventions beyond pharmacologic prophylaxis and slow ascent and may even preclude future travel to high altitude. This review considers this situation in greater detail. Structured around the case of an otherwise healthy 27-year-old individual with recurrent episodes of HAPE who would like to climb Denali (6,190 m), the review examines the known risk factors for disease and then provides guidance regarding when and how to evaluate such individuals and appropriate steps to prevent HAPE on further ascents to high elevation. Except in rare circumstances, a history of recurrent HAPE does not preclude further ascent to high elevation, as a multipronged approach including pharmacologic prophylaxis, careful planning about the rate of ascent, and the degree of physical effort and other strategies, such as preacclimatization, staged ascent, and use of hypoxic tents, can be employed to reduce the risk of recurrence with future travel.

Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?

Altitude-Related Disorders on Mount Kilimanjaro, Tanzania: Two-Year Survey in a Local Referral Center

Severe high-altitude cerebral edema on the Inca Trail

Clinical features of patients with severe altitude illness in Nepal

Acute high-altitude sickness

Research advances in pathogenesis and prophylactic measures of acute high altitude illness

Elevated C-Reactive Protein Augments Increased Arterial Stiffness in Subjects With the Metabolic Syndrome

A trek to the top: a review of acute mountain sickness

High-altitude cerebral edema with absence of headache

Mitral valve obstruction in a case of bacterial endocarditis due to Corynebacterium hofmanii: echocardiographic diagnosis.

High-altitude Cerebral Edema and High-altitude Pulmonary Edema Diagnosed in the Desert: A Case Report

Altitude illnesses

Atypical High-Altitude Cerebral Edema Presentation at an Altitude of Less Than 3000 Meters Elevation: A Case Report

Intraocular pressure effects of multiple doses of drugs applied to glaucomatous monkey eyes.

ATP Depletion-induced Actin Rearrangement Reduces Cell Adhesion via p38 MAPK-HSP27 Signaling in Renal Proximal Tubule Cells

Effect of penetration enhancers and iontophoresis on the ultrastructure and cholecystokinin-8 permeability through porcine skin.

Case report: Severe rhabdomyolysis and acute liver injury in a high-altitude mountain climber

Secundum Atrial Septal Defect: Nonoperative Closure During Cardiac Catheterization

Altitude-Related Illness

The impact of laws on HIV and STD prevention.

Evaluation and Management of the Individual with Recurrent High Altitude Pulmonary Edema